Price
No data yet.
Social Signal Score
Revenue
$0.00Company Profile
- CEO
- Michael Frank
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Employees
- 3
- Beta
- -1.88
- Country
- CA
- Piotroski score
- 2 / 9 (Weak)
- Altman Z-score
- -528.46
Financials
Net Income
$-507.8KEBITDA
$-462.8KFree Cash Flow
$-218.00EPS (diluted)
$-0.00Shares Outstanding (diluted)
435.68M+1633.2%Operating Expenses
$456.6KCash & Debt
$22.7KQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $0.00 | $-11.01M | $-0.03 |
| 2024 | $0.00 | $-5.62M | $-0.01 |
| 2023 | $0.00 | $-6.32M | $-0.02 |
| 2022 | $0.00 | $-17.81M | $-0.06 |
| 2021 | $0.00 | $-20.12M | $-0.08 |
| 2020 | $0.00 | $-5.38M | $-0.05 |
| 2019 | $0.00 | $-1.34M | $-0.02 |
| 2018 | $0.00 | $-1.79M | $-0.03 |
| 2017 | $0.00 | $-1.62M | $-0.03 |
| 2016 | $0.00 | $-2.74M | $-0.11 |
| 2015 | $0.00 | $-2.03M | $-0.09 |
| 2014 | $0.00 | $-1.26M | $-0.06 |
| 2013 | $0.00 | $-193.4K | $-0.02 |
Valuation
RVVTFhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
20-33.33%Social Signal Score
Mentions (5)
- Newsaccessnewswire.com·21d ago·Negative
…orphan diseases and government preparedness programs TORONTO, ON / ACCESS Newswire / September 15, 2026 / Revive Therapeutics Ltd. ("Revive" or the "Company") (OTCQB:RVVTF)(CSE:RVV)(Frankfurt:31R), a life sciences company focused on the research and development of therapeutics for biodefence and pandemic preparedness, today outlined its strategy to strengthen and expand the intellectual property and regulatory portfolio supporting bucillamine across medical countermeasures ("MCMs") and rare dise…
View source ↗ - Newsaccessnewswire.com·47d ago·Negative
…rapeutics Announces Proposed Shares for Debt Settlement TORONTO, ON / ACCESS Newswire / August 19, 2026 / Revive Therapeutics Ltd. ("Revive" or the "Company") (OTCQB:RVVTF)(CSE:RVV)(Frankfurt:31R), a life sciences company focused on the research and development of therapeutics for biodefence and pandemic preparedness, announces a proposed debt settlement pursuant to which the Company intends to issue up to 1,221,516 common shares in the capital of the Company (the "Settlement Shares") at a deeme…
View source ↗ - Newsaccessnewswire.com·48d ago·Negative
…ectual property and evaluate complementary therapeutics TORONTO, ON / ACCESS Newswire / August 19, 2026 / Revive Therapeutics Ltd. ("Revive" or the "Company") (OTCQB:RVVTF)(CSE:RVV)(Frankfurt:31R), a life sciences company focused on the research and development of therapeutics for biodefence and pandemic preparedness, today outlined its strategy to build a focused medical-countermeasure portfolio led by bucillamine.
View source ↗ - Newsaccessnewswire.com·52d ago·Negative
Revive Therapeutics Reports Grant of Options TORONTO, ON / ACCESS Newswire / August 14, 2026 / Revive Therapeutics Ltd. ("Revive" or the "Company") (OTCQB:RVVTF)(CSE:RVV)(Frankfurt:31R), a life sciences company focused on the research and development of therapeutics for biodefence and pandemic preparedness, today announced the Board of Directors of Revive has authorized the grant of an aggregate of 15,500,000 incentive stock options to key members of our team, including directors, officers, and …
View source ↗ - Newsaccessnewswire.com·55d ago·Negative
Revive Therapeutics Reports Positive Results from DRDC Bucillamine Nerve-Agent Research Study TORONTO, ON / ACCESS Newswire / August 12, 2026 / Revive Therapeutics Ltd. ("Revive" or the "Company") (OTCQB:RVVTF)(CSE:RVV)(Frankfurt:31R), a life sciences company focused on the research and development of therapeutics for biodefence and pandemic preparedness, today announced positive results from a research study conducted by Defence Research and Development Canada - Suffield Research Centre ("DRDC"
View source ↗
Congress trades
No disclosed congressional trades in RVVTF.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.